Emerald Mutual Fund Advisers Trust Purchases Shares of 9,138 ICU Medical, Inc. $ICUI

Emerald Mutual Fund Advisers Trust acquired a new position in ICU Medical, Inc. (NASDAQ:ICUI) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 9,138 shares of the medical instruments supplier’s stock, valued at approximately $1,096,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. AQR Capital Management LLC increased its position in ICU Medical by 2.5% in the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock worth $1,297,000 after purchasing an additional 229 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of ICU Medical by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after buying an additional 560 shares in the last quarter. United Services Automobile Association purchased a new stake in shares of ICU Medical during the 1st quarter valued at about $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of ICU Medical by 32.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock valued at $9,472,000 after acquiring an additional 16,680 shares during the last quarter. Finally, Intech Investment Management LLC grew its position in ICU Medical by 38.6% in the first quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock worth $1,658,000 after acquiring an additional 3,326 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ICUI shares. Piper Sandler upped their price objective on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Monday, January 19th. KeyCorp raised their price target on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $175.67.

ICU Medical Stock Down 3.7%

Shares of NASDAQ ICUI opened at $152.67 on Friday. ICU Medical, Inc. has a 52-week low of $107.00 and a 52-week high of $175.51. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of -492.47 and a beta of 0.80. The stock has a 50 day moving average price of $146.95 and a 200 day moving average price of $132.89. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.19 and a current ratio of 2.45.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The business had revenue of $533.30 million during the quarter, compared to analyst estimates of $511.46 million. During the same period in the previous year, the company posted $1.59 EPS. ICU Medical’s revenue was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Sell-side analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Insider Buying and Selling at ICU Medical

In related news, VP Virginia Ruth Sanzone sold 930 shares of ICU Medical stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total value of $132,376.20. Following the completion of the sale, the vice president directly owned 5,456 shares in the company, valued at $776,607.04. The trade was a 14.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Elisha W. Finney sold 1,285 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total transaction of $180,439.70. Following the transaction, the director owned 3,995 shares in the company, valued at approximately $560,977.90. The trade was a 24.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 1.50% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.